Disclosure of a transparency notification from Mawer Investment Management Ltd

Disclosure of a transparency notification from Mawer Investment Management Ltd




Disclosure of a transparency notification from Mawer Investment Management Ltd

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 13 March 2026 – 6 PM CET

Disclosure of a transparency notification from Mawer Investment Management Ltd

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Mawer Investment Management Ltd, dated 11 March 2026.

Notification from Mawer Investment Management Ltd

  • On 11 March 2026, Fagron received a transparency notification from Mawer Investment Management Ltd, informing the Company that its shareholding has crossed the 3% disclosure threshold downwards, following a disposal of voting securities or voting rights attached to shares in Fagron.
  • The notification was submitted by a person that notifies alone.
  • According to the notification, as of 10 March 2026, Mawer Investment Management Ltd holds a total of 2,188,313 shares in Fagron, corresponding to the same number of voting rights.
  • Based on the total number of outstanding voting rights (73,668,904 as the applicable denominator), this shareholding represents 2.97% of the total voting rights.
  • The full transparency notification from Mawer Investment Management Ltd is available on the Fagron website via the link.

Further information
Ignacio Artola
Global Head of Investor Relations
investors@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

Disclosure of a transparency notification from Mawer Investment Management Ltd

Disclosure of a transparency notification from Mawer Investment Management Ltd




Disclosure of a transparency notification from Mawer Investment Management Ltd

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 13 March 2026 – 6 PM CET

Disclosure of a transparency notification from Mawer Investment Management Ltd

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Mawer Investment Management Ltd, dated 11 March 2026.

Notification from Mawer Investment Management Ltd

  • On 11 March 2026, Fagron received a transparency notification from Mawer Investment Management Ltd, informing the Company that its shareholding has crossed the 3% disclosure threshold downwards, following a disposal of voting securities or voting rights attached to shares in Fagron.
  • The notification was submitted by a person that notifies alone.
  • According to the notification, as of 10 March 2026, Mawer Investment Management Ltd holds a total of 2,188,313 shares in Fagron, corresponding to the same number of voting rights.
  • Based on the total number of outstanding voting rights (73,668,904 as the applicable denominator), this shareholding represents 2.97% of the total voting rights.
  • The full transparency notification from Mawer Investment Management Ltd is available on the Fagron website via the link.

Further information
Ignacio Artola
Global Head of Investor Relations
investors@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure




Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.

Tevogen.AI was built to solve a critical challenge in drug development: identifying biological targets which are most likely to work in patients, before entering costly clinical trials.

Over the past year, the Company has built a proprietary database of more than 655 million peptide sequences derived from approximately 24 million proteins, representing nearly 16 billion data points across multiple disease areas. This database is continuously enriched using analysis of 37 million scientific publications.

Improved Prediction Accuracy

In recent beta testing of its PredicTcell™ model, Tevogen reported:

  • Recall improved from 87% to 92% (the model is finding more of the right targets)
  • Precision improved from 40% to 48% (fewer incorrect predictions)
  • Higher overall accuracy scores
  • Increased true positives and reduced missed targets
  • Dramatically expanded training sample size

These results allow the model to improve in identifying which immune targets are likely to succeed. The current version, trained on 1.8 million data points, is nearly 20 times more robust than the initial model, reflecting rapid scale and learning acceleration.

Drug development today relies heavily on trial-and-error, and by improving target prediction before clinical testing, Tevogen aims to:

  • Reduce time to market
  • Lower development costs
  • Increase probability of clinical success
  • Extend the value of patent-protected products

This development builds on Tevogen.AI’s  published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.

Production AI Agents and Continuous Learning

Tevogen.AI now operates three production AI agents that:

  1. Continuously evaluate 14 active peptide candidates
  2. Monitor newly published scientific literature
  3. Integrate wet lab results back into the AI system

This creates a continuous learning loop between AI predictions and biological validation, strengthening future performance.

Next Steps and Partnership Strategy

As predictive accuracy continues to improve, Tevogen intends to explore partnerships with pharmaceutical companies to advance select peptide candidates for production and development.

Mittul Mehta, CIO & Head of Tevogen.AI, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.”

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e46645d4-7bf3-4cb6-91d3-cb7ede5a0064

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure




Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.

Tevogen.AI was built to solve a critical challenge in drug development: identifying biological targets which are most likely to work in patients, before entering costly clinical trials.

Over the past year, the Company has built a proprietary database of more than 655 million peptide sequences derived from approximately 24 million proteins, representing nearly 16 billion data points across multiple disease areas. This database is continuously enriched using analysis of 37 million scientific publications.

Improved Prediction Accuracy

In recent beta testing of its PredicTcell™ model, Tevogen reported:

  • Recall improved from 87% to 92% (the model is finding more of the right targets)
  • Precision improved from 40% to 48% (fewer incorrect predictions)
  • Higher overall accuracy scores
  • Increased true positives and reduced missed targets
  • Dramatically expanded training sample size

These results allow the model to improve in identifying which immune targets are likely to succeed. The current version, trained on 1.8 million data points, is nearly 20 times more robust than the initial model, reflecting rapid scale and learning acceleration.

Drug development today relies heavily on trial-and-error, and by improving target prediction before clinical testing, Tevogen aims to:

  • Reduce time to market
  • Lower development costs
  • Increase probability of clinical success
  • Extend the value of patent-protected products

This development builds on Tevogen.AI’s  published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.

Production AI Agents and Continuous Learning

Tevogen.AI now operates three production AI agents that:

  1. Continuously evaluate 14 active peptide candidates
  2. Monitor newly published scientific literature
  3. Integrate wet lab results back into the AI system

This creates a continuous learning loop between AI predictions and biological validation, strengthening future performance.

Next Steps and Partnership Strategy

As predictive accuracy continues to improve, Tevogen intends to explore partnerships with pharmaceutical companies to advance select peptide candidates for production and development.

Mittul Mehta, CIO & Head of Tevogen.AI, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.”

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e46645d4-7bf3-4cb6-91d3-cb7ede5a0064

How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See

How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See




How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See

  • The Human Vascular System Stretches Up to 100,000 Miles — Standard Imaging Captures Only a Fraction of It
  • The Endothelial Glycocalyx: A Microscopic Lining That Helps Regulate How Blood Moves Through the Smallest Vessels
  • How Patented Microfluidic Chip Technology Allows Researchers to Study Vascular Function Under Realistic Conditions
  • What This Means for the Millions of People Searching for Answers About Circulation, Energy, and Whole-Body Vitality

A closer look at how microcirculation research is expanding what we understand about blood flow, oxygen delivery, and why the body’s smallest vessels may matter more than the largest ones

Scottsdale, AZ, March 13, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational vascular health, has published a comprehensive educational resource on microcirculation, blood flow, and the endothelial glycocalyx — the micro-thin, gel-like lining that coats the inside of every blood vessel in the body. The resource explores why this recently discovered structure is foundational to vascular health and total-body vitality, and why standard medical imaging often cannot assess the very network where oxygen and nutrient delivery actually occurs.

The cardiovascular system is frequently visualized as a network of major arteries and veins — the primary conduits that transport blood to and from the heart. While these large vessels are essential for systemic circulation, they represent a small chapter of a much larger biological story.

The vast majority of the vascular network is composed of microscopic vessels so narrow that red blood cells must travel single file to pass through them. This is the microcirculation — the capillary-level system where oxygen and nutrients are delivered directly to tissue.

Standard medical imaging tools, including CT scans and angiograms, are designed to evaluate the body’s primary supply routes. They can confirm that the main conduits are open and functioning. However, these tools lose resolution long before they reach the capillary beds where the final exchange between blood and tissue actually occurs.

“I often use a tree analogy,” explains Dr. Joel Kahn, MD, known as “America’s Holistic Heart Doc” and best-selling author and integrative cardiologist at the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and a frequent educator for Calroy Health Sciences.. “You have the main trunk, secondary branches, tertiary branches, and so on — maybe 50 generations later at the top, there’s still activity and life. The arterial system works the same way. We can image the main trunk and maybe three or four generations of branches, but we’re really limited in imaging the microcirculation — that 10th, 40th, 50th generation of vessels.”

This technological limitation means it is entirely possible for someone to pass a standard vascular screening with clear results while still experiencing fatigue, cold extremities, or mental fog — signals that may reflect what is happening at the microvascular level, not the arterial level.

Lining the interior of every blood vessel in the body is a delicate, gel-like structure known as the endothelial glycocalyx (EGX). Only recently discovered and often overlooked, this micro-thin lining is foundational to vascular health and total-body vitality. It performs critical functions: it acts as a semi-permeable barrier, it facilitates smooth blood flow, and it houses the enzymes involved in the production of nitric oxide — the molecule, first identified in Nobel Prize–winning research, that signals blood vessels to relax and support healthy circulation.

“There’s a single layer of cells — the endothelium — that separates the blood inside a blood vessel from the artery wall structure,” notes Dr. Kahn. “It’s almost like a Spanish-style tile floor of interlocking cells. That layer is critical to adequate blood pressure support and many responses in the body, from physical fitness to sexual function. You need a healthy endothelium. The glycocalyx sits on top of the endothelium, which consists of hair-like, protein-sugar structures resembling cake frosting. It’s very dynamic. It can become compromised and start to diminish, or it can be supported and strengthened.”

When the glycocalyx is supported, it helps maintain the slippery-smooth quality of the vessel interior — facilitating the efficient transit of red blood cells through capillaries and supporting nutrient and oxygen delivery at the tissue level. Peer-reviewed research has examined specific markers of vascular elasticity and endothelial integrity that may be associated with this structure’s function.

For decades, vascular research relied on static testing environments — observing cells in a stationary petri dish. While informative, this approach could not capture the dynamic behavior of the EGX under the physical shear stress of flowing blood.

Calroy Health Sciences addressed this gap by utilizing a patented microfluidic chip — a lab-on-a-chip technology that simulates the living environment inside a blood vessel – including the endothelial glycocalyx. Instead of testing compounds in a motionless setting, researchers can observe the endothelial glycocalyx in a dynamic state, under conditions that more closely mirror what happens inside the human body.

Through this approach, Calroy identified Monostroma nitidum, a rare marine algae containing the sulfated polysaccharide Rhamnan sulfate. A patented extract of this compound, trademarked as MonitumRS®, became the core of Arterosil HP® — a dietary supplement specifically formulated to support the integrity of the endothelial glycocalyx.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*†

Millions of people turn to search engines and AI tools every month asking about blood flow and circulation. In most cases, they are not looking for a clinical label — they are trying to make sense of the subtle shifts they experience throughout the day: afternoon energy dips, cold fingers and toes, or thinking that feels less sharp than it used to.

The language people use — “How do I support circulation?” — is often a description of microvascular function. The experience of “flow” is frequently the experience of capillary efficiency, governed by the very structure that standard imaging cannot see. As vascular research continues to advance, the endothelial glycocalyx is emerging as a foundational area of focus for understanding how the body delivers oxygen and nutrients to every organ, every day.

To learn more about how microcirculation, blood flow, and the endothelial glycocalyx influence vascular function, energy, cognition, and whole-body vitality, read the full educational resource from Calroy Health Sciences: Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx.

FREQUENTLY ASKED QUESTIONS

What is microcirculation and why does it matter?

Microcirculation refers to the network of microscopic blood vessels — capillaries, arterioles, and venules — where the body’s actual exchange of oxygen and nutrients at the tissue level takes place. While the heart and major arteries are responsible for bulk transport, it is the microcirculation that determines whether oxygen and nutrients reach their final destination. The human vascular system stretches approximately 60-100,000 miles, and the vast majority of that distance exists at the capillary level. Supporting healthy microcirculation is foundational to whole-body vitality, including energy, cognition, and vascular well-being.* Every organ and system in the body from the brain, to sexual organs, to the joints rely on healthy microcirculation to function.* Calroy Health Sciences has published a comprehensive educational resource on this topic at calroy.com/education/microcirculation-and-blood-flow/.

What is the endothelial glycocalyx?

The endothelial glycocalyx (EGX) is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel in the body. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation. When the glycocalyx is strong and healthy, circulation is supported and every organ feels the impact.

Why do standard heart health screenings sometimes miss what people actually feel?

Standard imaging tools like CT scans and angiograms are designed to evaluate large vessels — the body’s primary supply routes. They can confirm that the main conduits are open. However, they lose resolution before reaching the capillary beds where the actual exchange between blood and tissue occurs. This means it is possible to receive clear results from a standard vascular screening while still experiencing everyday shifts like fatigue, cold extremities, mental fog, or changes in sexual wellness — signals that may relate to microvascular function rather than large-vessel mechanics.

How does Calroy Health Sciences study vascular function differently?

Calroy utilizes a patented microfluidic chip — a lab-on-a-chip technology that simulates the living environment inside a blood vessel. Unlike static testing methods, this approach replicates the physical shear stress of flowing blood, allowing researchers to observe the endothelial glycocalyx in a dynamic state. Through this technology, Calroy identified and validated MonitumRS® (Rhamnan sulfate from Monostroma nitidum), the proprietary extract at the core of Arterosil HP® with MonitumRS®, which is specifically formulated to support the integrity of the endothelial glycocalyx.* Calroy’s published research is available in peer-reviewed journals.

What is MonitumRS® and how is it different from other vascular support ingredients?

MonitumRS® is a proprietary extract of Rhamnan sulfate derived from Monostroma nitidum, a rare marine algae. It is the core ingredient in Arterosil HP® with MonitumRS®. What distinguishes it is that it works. In the microfluidic chip study, it repaired the glucose-damaged endothelial glycocalyx cells up 103.8% from baseline in just 24 hours.*†

†As demonstrated in an independent third-party laboratory in vitro study.

Does circulation affect brain function and cognition?

The brain is one of the body’s most oxygen-dependent organs. It relies on continuous, efficient blood flow to support cognitive function, mental clarity, and focus throughout the day. Because the brain’s oxygen supply depends on the microvascular delivery network — not just the major arteries — the health of the microcirculation and the endothelial glycocalyx are foundational to cognitive well-being. Supporting healthy circulation means supporting the system that delivers oxygen and nutrients to the brain at the tissue level.

What is nitric oxide and what role does it play in circulation?

Nitric oxide (NO) is a tiny molecule naturally produced by the body that plays a central role in the cardiovascular system. First identified in Nobel Prize–winning research, it helps blood vessels relax and widen, supporting healthy circulation and helping maintain healthy blood pressure already in the normal range.* The endothelial glycocalyx houses the enzymes responsible for nitric oxide production, making the health of this microscopic lining essential to the body’s ability to maintain vascular tone and flexibility.

PUBLISHED RESEARCH & RESOURCES

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See

How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See




How Scientists Measure the Circulation You Actually Feel — Not Just the Arteries They Can See

  • The Human Vascular System Stretches Up to 100,000 Miles — Standard Imaging Captures Only a Fraction of It
  • The Endothelial Glycocalyx: A Microscopic Lining That Helps Regulate How Blood Moves Through the Smallest Vessels
  • How Patented Microfluidic Chip Technology Allows Researchers to Study Vascular Function Under Realistic Conditions
  • What This Means for the Millions of People Searching for Answers About Circulation, Energy, and Whole-Body Vitality

A closer look at how microcirculation research is expanding what we understand about blood flow, oxygen delivery, and why the body’s smallest vessels may matter more than the largest ones

Scottsdale, AZ, March 13, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational vascular health, has published a comprehensive educational resource on microcirculation, blood flow, and the endothelial glycocalyx — the micro-thin, gel-like lining that coats the inside of every blood vessel in the body. The resource explores why this recently discovered structure is foundational to vascular health and total-body vitality, and why standard medical imaging often cannot assess the very network where oxygen and nutrient delivery actually occurs.

The cardiovascular system is frequently visualized as a network of major arteries and veins — the primary conduits that transport blood to and from the heart. While these large vessels are essential for systemic circulation, they represent a small chapter of a much larger biological story.

The vast majority of the vascular network is composed of microscopic vessels so narrow that red blood cells must travel single file to pass through them. This is the microcirculation — the capillary-level system where oxygen and nutrients are delivered directly to tissue.

Standard medical imaging tools, including CT scans and angiograms, are designed to evaluate the body’s primary supply routes. They can confirm that the main conduits are open and functioning. However, these tools lose resolution long before they reach the capillary beds where the final exchange between blood and tissue actually occurs.

“I often use a tree analogy,” explains Dr. Joel Kahn, MD, known as “America’s Holistic Heart Doc” and best-selling author and integrative cardiologist at the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and a frequent educator for Calroy Health Sciences.. “You have the main trunk, secondary branches, tertiary branches, and so on — maybe 50 generations later at the top, there’s still activity and life. The arterial system works the same way. We can image the main trunk and maybe three or four generations of branches, but we’re really limited in imaging the microcirculation — that 10th, 40th, 50th generation of vessels.”

This technological limitation means it is entirely possible for someone to pass a standard vascular screening with clear results while still experiencing fatigue, cold extremities, or mental fog — signals that may reflect what is happening at the microvascular level, not the arterial level.

Lining the interior of every blood vessel in the body is a delicate, gel-like structure known as the endothelial glycocalyx (EGX). Only recently discovered and often overlooked, this micro-thin lining is foundational to vascular health and total-body vitality. It performs critical functions: it acts as a semi-permeable barrier, it facilitates smooth blood flow, and it houses the enzymes involved in the production of nitric oxide — the molecule, first identified in Nobel Prize–winning research, that signals blood vessels to relax and support healthy circulation.

“There’s a single layer of cells — the endothelium — that separates the blood inside a blood vessel from the artery wall structure,” notes Dr. Kahn. “It’s almost like a Spanish-style tile floor of interlocking cells. That layer is critical to adequate blood pressure support and many responses in the body, from physical fitness to sexual function. You need a healthy endothelium. The glycocalyx sits on top of the endothelium, which consists of hair-like, protein-sugar structures resembling cake frosting. It’s very dynamic. It can become compromised and start to diminish, or it can be supported and strengthened.”

When the glycocalyx is supported, it helps maintain the slippery-smooth quality of the vessel interior — facilitating the efficient transit of red blood cells through capillaries and supporting nutrient and oxygen delivery at the tissue level. Peer-reviewed research has examined specific markers of vascular elasticity and endothelial integrity that may be associated with this structure’s function.

For decades, vascular research relied on static testing environments — observing cells in a stationary petri dish. While informative, this approach could not capture the dynamic behavior of the EGX under the physical shear stress of flowing blood.

Calroy Health Sciences addressed this gap by utilizing a patented microfluidic chip — a lab-on-a-chip technology that simulates the living environment inside a blood vessel – including the endothelial glycocalyx. Instead of testing compounds in a motionless setting, researchers can observe the endothelial glycocalyx in a dynamic state, under conditions that more closely mirror what happens inside the human body.

Through this approach, Calroy identified Monostroma nitidum, a rare marine algae containing the sulfated polysaccharide Rhamnan sulfate. A patented extract of this compound, trademarked as MonitumRS®, became the core of Arterosil HP® — a dietary supplement specifically formulated to support the integrity of the endothelial glycocalyx.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*†

Millions of people turn to search engines and AI tools every month asking about blood flow and circulation. In most cases, they are not looking for a clinical label — they are trying to make sense of the subtle shifts they experience throughout the day: afternoon energy dips, cold fingers and toes, or thinking that feels less sharp than it used to.

The language people use — “How do I support circulation?” — is often a description of microvascular function. The experience of “flow” is frequently the experience of capillary efficiency, governed by the very structure that standard imaging cannot see. As vascular research continues to advance, the endothelial glycocalyx is emerging as a foundational area of focus for understanding how the body delivers oxygen and nutrients to every organ, every day.

To learn more about how microcirculation, blood flow, and the endothelial glycocalyx influence vascular function, energy, cognition, and whole-body vitality, read the full educational resource from Calroy Health Sciences: Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx.

FREQUENTLY ASKED QUESTIONS

What is microcirculation and why does it matter?

Microcirculation refers to the network of microscopic blood vessels — capillaries, arterioles, and venules — where the body’s actual exchange of oxygen and nutrients at the tissue level takes place. While the heart and major arteries are responsible for bulk transport, it is the microcirculation that determines whether oxygen and nutrients reach their final destination. The human vascular system stretches approximately 60-100,000 miles, and the vast majority of that distance exists at the capillary level. Supporting healthy microcirculation is foundational to whole-body vitality, including energy, cognition, and vascular well-being.* Every organ and system in the body from the brain, to sexual organs, to the joints rely on healthy microcirculation to function.* Calroy Health Sciences has published a comprehensive educational resource on this topic at calroy.com/education/microcirculation-and-blood-flow/.

What is the endothelial glycocalyx?

The endothelial glycocalyx (EGX) is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel in the body. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation. When the glycocalyx is strong and healthy, circulation is supported and every organ feels the impact.

Why do standard heart health screenings sometimes miss what people actually feel?

Standard imaging tools like CT scans and angiograms are designed to evaluate large vessels — the body’s primary supply routes. They can confirm that the main conduits are open. However, they lose resolution before reaching the capillary beds where the actual exchange between blood and tissue occurs. This means it is possible to receive clear results from a standard vascular screening while still experiencing everyday shifts like fatigue, cold extremities, mental fog, or changes in sexual wellness — signals that may relate to microvascular function rather than large-vessel mechanics.

How does Calroy Health Sciences study vascular function differently?

Calroy utilizes a patented microfluidic chip — a lab-on-a-chip technology that simulates the living environment inside a blood vessel. Unlike static testing methods, this approach replicates the physical shear stress of flowing blood, allowing researchers to observe the endothelial glycocalyx in a dynamic state. Through this technology, Calroy identified and validated MonitumRS® (Rhamnan sulfate from Monostroma nitidum), the proprietary extract at the core of Arterosil HP® with MonitumRS®, which is specifically formulated to support the integrity of the endothelial glycocalyx.* Calroy’s published research is available in peer-reviewed journals.

What is MonitumRS® and how is it different from other vascular support ingredients?

MonitumRS® is a proprietary extract of Rhamnan sulfate derived from Monostroma nitidum, a rare marine algae. It is the core ingredient in Arterosil HP® with MonitumRS®. What distinguishes it is that it works. In the microfluidic chip study, it repaired the glucose-damaged endothelial glycocalyx cells up 103.8% from baseline in just 24 hours.*†

†As demonstrated in an independent third-party laboratory in vitro study.

Does circulation affect brain function and cognition?

The brain is one of the body’s most oxygen-dependent organs. It relies on continuous, efficient blood flow to support cognitive function, mental clarity, and focus throughout the day. Because the brain’s oxygen supply depends on the microvascular delivery network — not just the major arteries — the health of the microcirculation and the endothelial glycocalyx are foundational to cognitive well-being. Supporting healthy circulation means supporting the system that delivers oxygen and nutrients to the brain at the tissue level.

What is nitric oxide and what role does it play in circulation?

Nitric oxide (NO) is a tiny molecule naturally produced by the body that plays a central role in the cardiovascular system. First identified in Nobel Prize–winning research, it helps blood vessels relax and widen, supporting healthy circulation and helping maintain healthy blood pressure already in the normal range.* The endothelial glycocalyx houses the enzymes responsible for nitric oxide production, making the health of this microscopic lining essential to the body’s ability to maintain vascular tone and flexibility.

PUBLISHED RESEARCH & RESOURCES

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases

ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases




ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases

Key Highlights

  • Ongoing open-ended discretionary stock purchases by the president and chairman, demonstrating confidence in TXTM’s growth and future.
  • No salaries paid from inception to date, ensuring financial discipline and no dilution.
  • The company has not had any reverse stock splits to date, protecting value for shareholders.
  • Strategic liquidity arrangements with BNY Mellon, Standard Bank, Absa, and Melville Douglas.
  • Custodial wallet pilot program supporting foreign direct trade and the influx of foreign equities.
  • Tokenization of RWAs, providing greater liquidity, capital flexibility, and global scalability.
  • Proprietary kettle tech

FORT LAUDERDALE, Fla., March 13, 2026 (GLOBE NEWSWIRE) — ProText Mobility Inc. (OTC: TXTM), a biotech company and leader in blockchain-enabled asset tokenization and compliant Real-World Asset (RWA) solutions, is excited to provide an important strategic update to its shareholders and investors. ProText is aggressively advancing its uplisting efforts, unlocking hidden value, and taking significant strides toward global market leadership.

Unwavering Confidence: Open-Ended Stock Purchases

The president and chairman of ProText Mobility Inc. has continued to only buy and accumulate shares, with no sales ever made. This shows strong confidence in the company’s growth potential, especially as ProText moves forward with its uplisting and Deloitte valuation. The president’s commitment will accelerate, with aggressive stock purchases to address the disparity between the current stock price and the company’s intrinsic value.

No Salaries, No Reverse Split

ProText remains steadfast in its commitment to financial discipline, having never paid salaries to any of its executives from inception to date. This ensures that the company’s focus remains on creating shareholder value, with no dilution or unnecessary financial overhead. The company has not had any reverse stock splits to date, further protecting shareholders from any dilution-related impact. ProText maintains zero debt, strong financial health, and a balanced, focused approach to growth.

Strategic Liquidity Arrangements with Major Banks

In alignment with its global expansion goals, ProText has secured liquidity arrangements for TXTM common stock via custodial wallets with BNY Mellon, Standard Bank, Melville Douglas, and Absa. These relationships allow ProText to leverage its stock for growth, expand its capital base, and execute on its strategic goals. ProText is also advancing its custodial wallet pilot program, which is key to its foreign direct trade initiatives and the influx of foreign equities.

Tokenization and Financial Flexibility

ProText’s access to blockchain-enabled RWA tokenization platform is at the forefront of transforming real-world assets into digital tokens, enabling capital flexibility and opening new liquidity pathways. ProText’s access to platform allows for the interchangeability between fiat and digital assets, enhancing market scalability and liquidity. This will empower ProText to expand rapidly into new markets, creating immense growth opportunities for the company.

Leveraging Proprietary Kettle Tech & Nano Technology for Exponential Tokenization Potential

ProText’s proprietary kettle tech and nano-technology continue to enhance the company’s tokenization capabilities by improving the bioavailability of physical assets, particularly Active Pharmaceutical Ingredients (APIs). This increased bioavailability offers exponential potential for the tokenization of APIs and other key assets that the company works with. By enabling faster absorption and enhanced efficacy of these assets, ProText can not only accelerate the development of new digital assets but also unlock new revenue streams within the biotech and pharmaceutical sectors.

This advancement positions ProText at the forefront of a transformative shift in how APIs are handled and tokenized, creating valuable opportunities for global scalability and growth.

HULE Investment Strategy: Reinvestment Loop Adding Value

A key strategic element in ProText’s long-term growth is the HULE investment strategy, a powerful model for creating a reinvestment loop that drives both balance sheet value and franchise growth.

By reinvesting capital into the company, ProText is able to fuel its growth and maximize shareholder value. The HULE strategy centers around compounding returns through strategic, institutional-grade investments that feed back into the company, enhancing both its market position and financial health.

This self-sustaining loop works by utilizing capital efficiencies and focused reinvestment to not only bolster the balance sheet but also position ProText for long-term growth. The HULE strategy’s impact is clear: it provides ProText with the ability to accelerate its value creation, increase its franchise strength, and ultimately lead to stock price appreciation as the company continues to scale.

The HULE investment strategy doesn’t just provide capital flexibility, but also creates a predictable, scalable growth model that powers ProText’s expansion, increasing operating leverage and market competitiveness.

Seed Stock and IFRS Boost to the Balance Sheet

ProText’s seed stock held on the balance sheet will now see a significant boost under the new IFRS standards. As the company moves toward IFRS-compliant audited financials, the seed stock value, which has been building steadily, will gain recognition in line with global accounting standards. This IFRS treatment will not only enhance the balance sheet but also help in unlocking additional value for ProText, driving higher franchise value and positioning the company for further growth and stock price appreciation.

Uplisting to a Major Exchange

The company is actively working toward its uplisting to a major exchange. The completion of IFRS-compliant audited financials is a critical step toward achieving this goal. By adhering to international accounting standards, ProText is positioning itself for a seamless transition to a major exchange, enhancing its market visibility and opening the door for institutional investors.

TruLeaf LOI: Unlocking Hidden IFRS Value

As part of its IFRS-driven strategy, the TruLeaf Letter of Intent (LOI) will unlock hidden value in the company’s balance sheet. Under the new IFRS standards, the TruLeaf deal will release this value, providing a spring-loaded macro tailwind for ProText as it advances its uplisting. The TruLeaf agreement is a key element in ProText’s strategy to re-book hidden value, enhancing its overall valuation and positioning it for future growth.

New Corporate Website, IR Suite, and EDGAR Reporting

ProText is in the final stages of launching its super high-tech corporate website, which will feature an integrated IR suite for real-time shareholder communication. This platform will allow for instant updates, ensuring transparency and engagement with investors.

Additionally, the company is moving toward voluntary EDGAR reporting, reinforcing its commitment to corporate governance and providing investors with real-time access to financial information. This enhances trust and underscores ProText’s commitment to transparency and best practices.

IFRS-Audited Financials and Uplisting Plans

ProText’s focus on IFRS-compliant audited financials is key to its uplisting strategy. The company is ensuring that it meets the required accounting standards, which will enhance its credibility in the eyes of institutional investors. The Deloitte valuation will be a critical step in proper price discovery and will assist in ensuring that the company is properly valued as it moves toward its uplisting to a major exchange.

Foreign Exchange Tailwinds and Profit Potential

ProText is well-positioned to take advantage of foreign exchange tailwinds, particularly as the USD weakens against the ZAR. As the USD/ZAR exchange rate continues to shift, ProText stands to gain not only revenue but also profit, further strengthening its financial position.

ProText’s ability to tokenize assets while capturing value from favorable forex fluctuations presents a significant opportunity for growth, making the company well-positioned for international expansion.

Sustainability and ESG Strategy

ProText’s commitment to sustainability is integral to its business model. The company is actively working to integrate carbon credits into its tokenization system, aligning with its zero-waste business model. As part of its broader ESG strategy, ProText is focused on environmental, social, and governance initiatives that support economic recovery and create long-term shareholder value.

About ProText Mobility, Inc. (OTC: TXTM)

ProText Mobility focuses on the research, testing, and development of highly bioavailable botanical formulations for nutraceutical and pharmaceutical applications. Through proprietary live-plant extraction technologies, the company aims to advance plant-based therapeutics that address global wellness and health needs.

Investor & Media Contact:
Dylon Du Plooy – dylon@rsammd.co.za
Dr. J – exportintl@aol.com

Website: https://ir.protxtm.com/

Follow Us:
X (Twitter): https://x.com/ProtextP

Forward-Looking Statements

This press release is provided solely as a general business update and does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Certain statements contained herein are forward-looking statements, including but not limited to statements regarding the Company’s anticipated audit timing, financial reporting plans, potential corporate name or ticker symbol changes, possible reverse stock split considerations, board composition efforts, credit facility discussions, registration statement process, and any potential uplisting or national exchange strategy.

These forward-looking statements are based on current expectations, assumptions, and internal planning, all of which are subject to substantial risks, uncertainties, regulatory review, market conditions, third-party actions, and other factors, many of which are outside the Company’s control. There can be no assurance that any audit will be completed by any particular date, that any registration statement will become effective, that any financing facility will be secured, that any corporate action will occur, or that the Company will satisfy the requirements for or successfully complete any uplisting or exchange listing.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update these statements except as required by applicable law.

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row




New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Ranked Top 50 in the Nation for 2026

New York, NY, March 13, 2026 (GLOBE NEWSWIRE) — New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States.

This recognition reflects NYPS Group and Deep Blue Med Spa’s continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical professionals.

Allergan Aesthetics, an AbbVie company, develops and manufactures some of the most recognized brands in medical aesthetics, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers, Skinvive™, CoolSculpting®, CoolTone®, DiamondGlow®, and SkinMedica®, among others. Rankings are determined through the Allergan Partner Privileges program, which acknowledges practices based on their experience and volume of Allergan aesthetic products and treatments.

Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive aesthetic services. National Top 50 placement further distinguishes the practices as leaders in the field.

“This continued recognition from Allergan Aesthetics reflects the dedication of our surgeons, physician assistants, nurse practitioners, and aesthetic providers who prioritize patient safety, education, and natural-looking results,” said NYPS Group President, Tommaso Addona, MD, FACS. “It is an honor and a privilege to serve our patients with advanced treatments backed by science and delivered with precision.”

For patients, this designation signals a high level of experience with Allergan’s portfolio of products and access to exclusive offerings and rewards through Allergan’s programs. It also reflects ongoing investment in provider training, as multiple NYPS Group and Deep Blue Med Spa clinicians have been selected to serve as national Allergan Medical Institute (AMI) trainers, contributing to peer education across the country.

About New York Plastic Surgical Group and Deep Blue Med Spa
As the largest and longest-running private and academic plastic surgery practice in the United States, New York Plastic Surgical Group includes more than 20 experienced plastic surgeons and maintains over 10 offices throughout the metropolitan area. In addition to its surgical practice, NYPS Group operates Deep Blue Med Spa, which provides non-surgical aesthetic treatments in multiple New York locations. Together, the practices are known for clinical excellence, comprehensive patient care, and a commitment to advancing the field of aesthetic medicine through education and innovation.

About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), develops, manufactures, and markets a portfolio of leading aesthetics brands and products worldwide. Its offerings include facial injectables, body contouring technologies, skin care, and more. Through ongoing research and innovation, Allergan Aesthetics remains committed to advancing science-based solutions in aesthetic medicine.

Attachment

CONTACT: Jeanine DiGennaro
Director of Marketing & Communications
(516) 629-3835
jdigennaro@nyplasticsurgical.com

New York Plastic Surgical Group
(516) 742-3404

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row




New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Ranked Top 50 in the Nation for 2026

New York, NY, March 13, 2026 (GLOBE NEWSWIRE) — New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States.

This recognition reflects NYPS Group and Deep Blue Med Spa’s continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical professionals.

Allergan Aesthetics, an AbbVie company, develops and manufactures some of the most recognized brands in medical aesthetics, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers, Skinvive™, CoolSculpting®, CoolTone®, DiamondGlow®, and SkinMedica®, among others. Rankings are determined through the Allergan Partner Privileges program, which acknowledges practices based on their experience and volume of Allergan aesthetic products and treatments.

Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive aesthetic services. National Top 50 placement further distinguishes the practices as leaders in the field.

“This continued recognition from Allergan Aesthetics reflects the dedication of our surgeons, physician assistants, nurse practitioners, and aesthetic providers who prioritize patient safety, education, and natural-looking results,” said NYPS Group President, Tommaso Addona, MD, FACS. “It is an honor and a privilege to serve our patients with advanced treatments backed by science and delivered with precision.”

For patients, this designation signals a high level of experience with Allergan’s portfolio of products and access to exclusive offerings and rewards through Allergan’s programs. It also reflects ongoing investment in provider training, as multiple NYPS Group and Deep Blue Med Spa clinicians have been selected to serve as national Allergan Medical Institute (AMI) trainers, contributing to peer education across the country.

About New York Plastic Surgical Group and Deep Blue Med Spa
As the largest and longest-running private and academic plastic surgery practice in the United States, New York Plastic Surgical Group includes more than 20 experienced plastic surgeons and maintains over 10 offices throughout the metropolitan area. In addition to its surgical practice, NYPS Group operates Deep Blue Med Spa, which provides non-surgical aesthetic treatments in multiple New York locations. Together, the practices are known for clinical excellence, comprehensive patient care, and a commitment to advancing the field of aesthetic medicine through education and innovation.

About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), develops, manufactures, and markets a portfolio of leading aesthetics brands and products worldwide. Its offerings include facial injectables, body contouring technologies, skin care, and more. Through ongoing research and innovation, Allergan Aesthetics remains committed to advancing science-based solutions in aesthetic medicine.

Attachment

CONTACT: Jeanine DiGennaro
Director of Marketing & Communications
(516) 629-3835
jdigennaro@nyplasticsurgical.com

New York Plastic Surgical Group
(516) 742-3404

Connected Innovation and Specialty-Specific AI Take Center Stage at Nextech EDGE 2026

Connected Innovation and Specialty-Specific AI Take Center Stage at Nextech EDGE 2026




Connected Innovation and Specialty-Specific AI Take Center Stage at Nextech EDGE 2026

TAMPA, Fla., March 13, 2026 (GLOBE NEWSWIRE) — Specialty leaders from across the country are gathering at Nextech EDGE 2026, the company’s annual user conference designed to bring together customers, partners, and industry experts to collaborate on the future of specialty care.

Running through March 14 in Orlando, Fla., EDGE creates a shared forum where practices exchange ideas, influence innovation, and explore existing technology built alongside the communities it serves. The event unites providers, administrators, executives, and technology leaders around a common goal of advancing specialty care through connected innovation and specialty-specific artificial intelligence (AI) designed to solve real practice challenges.

“EDGE is an opportunity for us to spend time directly with the practices we serve and better understand the unique demands of each specialty,” said Rusty Frantz, CEO of Nextech. “Those conversations help shape the innovations we’re building, including specialty-specific AI designed to align with real clinical workflows. By listening closely to our customers, we can deliver technology that reduces administrative burden, supports providers in the exam room, and ultimately helps practices deliver better care in a healthcare environment defined by constant change and rising expectations.”
  
Built around customer collaboration, EDGE 2026 highlights how Nextech innovations evolve through ongoing partnership with specialty practices. EDGE will spotlight the next evolution of the Nextech platform, including its new AI assistant alongside advancements in data insights, patient experience, and payments. Attendees will receive exclusive early access to these connected innovations, designed to help practices strengthen performance, protect margins, and elevate patient care through solutions shaped by real-world specialty workflows and feedback.

AI-Powered Clinical Documentation
Cora Scribe is Nextech’s recently launched AI assistant built specifically for ophthalmology. The two-way intelligently integrated scribe listens to natural conversations, understands clinical context, and automatically generates accurate, structured documentation inserted directly into the EHR in near real time.

A Smarter Data Foundation
Nextech is reimagining how data powers the specialty practice by modernizing reporting and standardizing insights across the platform. With a stronger data foundation, practices gain clearer visibility, greater confidence, and the ability to move faster, protect margins, and lead with clarity as innovation continues to unfold.

Patient Experience, Reimagined
EDGE will spotlight major enhancements across the entire patient journey, from smarter acquisition to seamless access and ongoing engagement. These connected innovations, integrated across Nextech solutions and alongside a new intelligent CRM, support personalized communication, referrals, and membership‑driven engagement, extending the patient experience beyond the visit.

Flexible, Frictionless, Embedded Payments
The company also will showcase enhancements to Nextech Payments and expanded offerings designed to deliver a more modern, connected financial experience for both patients and practices. Powered by enhanced payment processing capabilities through Stripe and expanded patient financing with Affirm, these innovations reflect the growing role payments play in the overall patient experience. As healthcare consumers expect greater transparency, flexibility, and convenience, practices benefit from embedded workflows, flexible payment choices, and a simplified end-to-end financial journey that supports access to care while strengthening financial performance.

Beyond product updates, EDGE will deliver two full days of educational sessions tailored to ophthalmology, dermatology, plastic surgery, and med spa practices. Attendees will also gain direct access to Nextech leadership, product experts, and peers, fostering collaborative learning and practical problem-solving.

To learn more about Nextech and its intelligent, connected solutions, visit www.nextech.com.

About Nextech  
Nextech provides intelligent, connected technology that helps specialty practices operate more easily and create meaningful patient experiences. With more than 25 years of expertise in ophthalmology, dermatology, orthopedics, plastic surgery, and med spas, Nextech blends specialty insight with thoughtful innovation to simplify workflows, reduce friction, and support practice growth.

CONTACT: Amanda Wratchford
Nextech Senior Vice President of Marketing
a.wratchford@nextech.com